<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Unfolding Story of Inclusion-Body Myositis and Myopathies: Role of Misfolded Proteins, Amyloid-␤, Cholesterol, and Aging</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Valerie</forename><surname>Askanas</surname></persName>
							<email>askanas@hsc.usc.edu</email>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">;</forename><forename type="middle">W</forename><surname>King Engel</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">USC Neuromuscular Center (Drs Askanas and Engel)</orgName>
								<orgName type="department" key="dep2">Department of Neurology</orgName>
								<orgName type="institution">University of Southern California Keck School of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution">Good Samaritan Hospital</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">USC Neuromuscular Center</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="institution">Good Samaritan Hospital</orgName>
								<address>
									<addrLine>637 S. Lucas Ave</addrLine>
									<postCode>90017-1912</postCode>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Unfolding Story of Inclusion-Body Myositis and Myopathies: Role of Misfolded Proteins, Amyloid-␤, Cholesterol, and Aging</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">4712FDE3F5460A1C333DBF85FBDD8ACC</idno>
					<note type="submission">Received Dec 11, 2002. Accepted for publication Dec 11, 2002.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Sporadic inclusion-body myositis is recognized as the most common muscle disease beginning after age 50 years, leading to severe disability. Sporadic inclusion-body myositis is of unknown cause and unconfirmed pathogenesis.</p><p>Traditionally, sporadic inclusion-body myositis has been considered an inflammatory myopathy, together with polymyositis and dermatomyositis, and several recent reviews addressed the inflammatory aspects of these disorders. 1-3 However, although the inflammatory component of sporadic inclusion-body myositis muscle biopsies is undisputable, at least in the early stages, patients with sporadic inclusion-body myositis, as a group, respond poorly to antidysimmune treatment, in contrast to patients with polymyositis and dermatomyositis. <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">4</ref> Patients over age 50 years with what could be considered "pure" polymyositis are rare; virtually all of the older patients with lymphocytic myositis have sporadic inclusion-body myositis.</p><p>An intriguing aspect of the sporadic inclusion-body myositis muscle-fiber molecular phenotype is its remarkable similarity to that of Alzheimer's disease brain (recently reviewed in Askanas and Engel 5 ). These similarities include accumulations of amyloid-␤ precursor protein, amyloid-␤, phosphorylated tau protein in the form of paired helical filaments, presenilin-1 protein, and several other "Alzheimercharacteristic proteins." <ref type="bibr" target="#b4">5</ref> In sporadic inclusion-body myositis, the milieu of the aging muscle fiber might (a) modify the provocation of, and/or response to, the lymphocytic inflammation 5 and (b) promote development of the inclusion-body myositis characteristic progressive vacuolar degeneration. Another possibility exists that lymphocytic inflammation might be a secondary component, occurring in response to "foreign" protein abnormally accumulated within and foreignizing sporadic inclusion-body myositis muscle fiber. This possibility can be supported by the fact that inflammation, in addition to other abnormalities, is present in the muscle of transgenic mice overexpressing amyloid-␤ precursor protein in muscle fibers. <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref> Moreover, lymphocytic inflammation 185</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>can occur in several human genetic muscle diseases, generally considered noninflammatory, including dysferlin deficiency, laminin-2 deficiency, and facioscapular muscular dystrophy. <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref> In 1993, we introduced the term hereditary inclusionbody myopathies to designate hereditary muscle diseases with pathologic features strikingly resembling those of sporadic inclusion-body myositis except for a lack of lymphocytic inflammation-hence the term "myopathy" instead of "myositis." <ref type="bibr" target="#b11">12</ref> The hereditary inclusion-body myopathies encompass several autosomal recessive and autosomal dominant syndromes of progressive muscle weakness with various clinical presentations (recently reviewed in Askanas and Engel <ref type="bibr" target="#b12">13</ref> ).</p><p>Because the characteristic pathologic phenotype of hereditary inclusion-body myopathies is now well defined, we consider all hereditary muscle diseases whose muscle biopsies contain vacuoles and both types of the characteristic inclusion-body myopathy-type inclusions (see below) to be forms of hereditary inclusion-body myopathies. The hereditary inclusion-body myopathies can be grouped by their mode of inheritance and genetic mutation (Table <ref type="table" target="#tab_0">1</ref>). <ref type="bibr" target="#b12">13</ref> We present a brief summary of clinical and pathologic features of sporadic inclusion-body myositis and hereditary inclusion-body myopathies, together referred to as "the IBMs," and discuss our current concepts of the pathogenesis including considerations as to how different etiologies can lead to very similar pathogenic cascades.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SPORADIC INCLUSION-BODY MYOSITIS: BRIEF SUMMARY OF CLINICAL FEATURES</head><p>The onset of sporadic inclusion-body myositis is usually after age 50 years, predominantly in men. <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b14">15</ref> The muscle weakness is both distal and proximal in the lower and upper limbs. The quadriceps is prominently involved. <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b14">15</ref> The slowly progressive course of sporadic inclusion-body myositis usually leads to severe disability and eventually to respiratory muscle weakness. Dysphagia is fairly common.</p><p>The late-juvenile sporadic inclusion-body myositis form was recently observed in three young unrelated males with a distribution of muscle weakness similar to that of sporadic inclusion-body myositis, but with onset age in their late teens (two patients) and at age 20 years (one patient). Their muscle biopsies had features of sporadic inclusion-body myositis, with some aspects of hereditary inclusion-body myopathies. We have proposed that yet unknown susceptibility genes are responsible for the early onset of sporadic inclusion-body myositis in these patients. <ref type="bibr" target="#b15">16</ref> We have recently emphasized the potential importance of susceptibility genes on the basis of a patient who had sporadic inclusion-body myositis and transthyretin gene mutation. <ref type="bibr" target="#b16">17</ref> This patient is a 70-year-old man homozygous for the transthyretin VAL122ILE mutation, who has both sporadic inclusion-body myositis and cardiac amyloidosis. <ref type="bibr" target="#b16">17</ref> Unique pathologic features of his muscle biopsy included prominent blood vessel congophilic amyloid immunoreactive for transthyretin and, within the vacuolated muscle fibers, congophilic deposits coimmunoreactive for both transthyretin and amyloid-␤.</p><p>Because wild transthyretin is known to sequester amyloid-␤ and to prevent fibrillogenesis, we suggest that the transthyretin mutation in this patient might be promoting the amyloid fibrillogenesis of amyloid-␤ within the muscle fibers and muscle blood vessels. In this particular patient, the senile cardiac amyloidosis, muscle blood vessel amyloidosis, and sporadic inclusion-body myositis all possibly relate to the transthyretin mutation, raising the possibility that otherwise benign mutations of various susceptibility genes can promote sporadic inclusion-body myositis in other patients. If the transthyretin VAL122ILE mutation was a factor in the sporadic inclusion-body myositis pathogenesis in our patient, it had existed since conception, but his muscle weakness did not develop until after the age of 60 years, suggesting the importance of an aging cellular environment in this process.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SUMMARY OF DIFFERENT FORMS OF HEREDITARY INCLUSION-BODY MYOPATHIES</head><p>Hereditary inclusion-body myopathies encompass several heterogeneic syndromes, each characterized by progressive muscle weakness but having different clinical manifestations. Hereditary inclusion-body myopathies are inherited either as an autosomal recessive or autosomal dominant trait. The clinical onset is usually in the second or third decade or sometimes earlier (a detailed review of various forms of hereditary inclusion-body myopathies is in Askanas and Engel <ref type="bibr" target="#b12">13</ref> ). Table <ref type="table" target="#tab_0">1</ref> illustrates our recent classification of hereditary inclusion-body myopathies, including recently identified mutated genes present in some forms.</p><p>Of particular interest are mutations identified in the GNE gene in quadriceps sparing hereditary inclusion-body myopathies in Persian Jews, Japanese patients, and other ethnic groups. <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref> UDP-N-acetylglucosamine 2-epimerase/Nacetylmannosamine kinase (GNE) is a bifunctional enzyme catalyzing the first two steps in the synthesis of N-acetylneuraminic (sialic) acid. <ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref> In hereditary inclusion-body myopathies, missense mutations were found in the kinase (amino terminus) and epimerase (carboxyl terminus) domains. <ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref> GNE modulates the structure of many protein complexes in virtually all organs. <ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref> GNE-dependent synthesis of sialic acid occurs in the cytoplasm (in addition, some sialic acid can be derived from several other sources, including cell-surface glycoproteins and lipids cleaved in the lysosomal compartment). Sialic acid is a terminal component of glycan structures bound to proteins and gangliosides. It is considered to play important roles in several cellular processes, including cellular adhesion, formation of and/or marking recognition sites for toxins and other pathogenic agents, stabilization of glycoprotein structures, signal transduction, and cell-mediated immune responses. <ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref> Because of the important cellular functions of sialic acid, any dysregulation of its biosynthesis and distribution can lead to severe abnormalities of glycoconjugate biosynthesis. <ref type="bibr" target="#b23">24</ref> The mechanism of how the mutations in the GNE gene lead to the development of the quadriceps sparing hereditary inclusion-body myopathies awaits clarification.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CHARACTERISTIC FEATURES OF SPORADIC INCLUSION-BODY MYOSITIS MUSCLE BIOPSIES</head><p>Characteristic light-microscopic features of sporadic inclusion-body myositis muscle biopsies are vacuolated muscle fibers and degrees of lymphocytic inflammation, with some macrophages, varying from abundant in early stages to little or none in later stages of involvement of the sampled muscle. Sixty to eighty percent of the sporadic inclusion-body myositis vacuolated muscle fibers contain, mainly in their nonvacuolated regions, foci of amyloid as defined by Congo red fluorescence visualized through Texas red filters. <ref type="bibr" target="#b24">25</ref> Ultrastructural abnormalities include the presence of characteristic clusters of 15 to 21 nm diameter paired helical filaments containing phosphorylated tau protein, <ref type="bibr" target="#b25">26</ref> located in both vacuolated and nonvacuolated muscle fibers, strikingly resembling paired helical filaments of Alzheimer's disease brain.</p><p>To diagnose sporadic inclusion-body myositis, we recommend that the following be performed on 10 m sections of a fresh-frozen muscle biopsy: (1) Engel-modifed trichrome stain to visualize, in addition to mononuclear cell inflammation and vacuolated muscle fibers, small angular fibers, ragged-red fibers, rare necrotizing fibers, and regen-degen fibers <ref type="bibr" target="#b26">27</ref> ; (2) fluorescence-enhanced Congo red stain <ref type="bibr" target="#b24">25</ref> ; (3) SMI-31 monoclonal antibody immunocytochemical staining, which recognizes the phosphorylated tau protein of paired helical filaments in sporadic inclusion-body myositis <ref type="bibr" target="#b25">26</ref> ; and (4) if SMI-31 antibody is not available, ubiquitin immunoreactivity within muscle fibers of sporadic inclusion-body myositis, which can be used to differentiate it from polymyositis. <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29</ref> We and others consider that there is an important denervation component in sporadic inclusion-body myositis. <ref type="bibr" target="#b4">5</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CHARACTERISTIC FEATURES OF HEREDITARY INCLUSION-BODY MYOPATHY MUSCLE BIOPSIES</head><p>Most of the pathologic features of the muscle biopsies of hereditary inclusion-body myopathies are similar to those of sporadic inclusion-body myositis, but hereditary inclusionbody myopathy muscle biopsies usually lack lymphocytic mononuclear inflammation. In contrast to the abnormal muscle fibers in sporadic inclusion-body myositis, in hereditary inclusion-body myopathies, most of the vacuolated muscle fibers do not contain Congo red positivity (with the exception of one autosomal dominant form whose muscle fibers and their nuclei contained large congophilic inclusions). <ref type="bibr" target="#b29">30</ref> Also, in contrast to the features of sporadic inclusion-body myositis, in hereditary inclusion-body myopathies, paired helical filaments lack some epitopes of phosphorylated tau protein, are not congophilic, and do not contain apolipoprotein-E. <ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32</ref> Therefore, in patients with hereditary inclusion-body myopathies, compared with those with sporadic inclusion-body myositis, muscle pathologic features seem somewhat less advanced, possibly owing to the younger age of the patients with hereditary inclusion-body myopathies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>POSSIBLE PATHOGENIC MECHANISMS OF SPORADIC AND HEREDITARY INCLUSION-BODY MYOPATHIES</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Specificity of the Inclusion-Body Myopathy Phenotype</head><p>The unusual constellations of proteins constituting the inclusion of inclusion-body myopathy abnormal muscle fibers are characteristic of sporadic inclusion-body myositis and hereditary inclusion-body myopathies and, in our experience, do not occur in either the vacuolated or nonvaculolated fibers of other muscle diseases. The only exception is oculopharyngeal muscular dystrophy, <ref type="bibr" target="#b32">33</ref> which, for this reason, can be considered a form of hereditary inclusionbody myopathy. <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b33">34</ref> The occasional vacuoles and tubulofilaments, reported in rare muscle fibers in a few other muscle diseases, for example, in patients with myotonic dystrophy (and, if so, in older patients [V. Askanas and W.K. Engel, unpublished observation, 1998]), are very sparse and probably not pathogenically significant for those diseases. We previously postulated that in the various inclusion-body myopathies, different etiologies lead to a downstream common pathogenic cascade, which ultimately is responsible for the characteristic muscle fiber degeneration. This would be the same principle as in Alzheimer's disease, in which at least five different genes (and other unknown factors) lead to the same pathologic phenotype in the brain. <ref type="bibr" target="#b34">35</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Possible Mechanisms Governing Formation of the Inclusion Bodies in the Inclusion-Body Myopathy Muscle</head><p>On a given section of an inclusion-body myopathy muscle biopsy, the inclusion bodies are present mainly in the vacuolefree regions of the vacuolated muscle fiber cytoplasm and in the cytoplasm of the nonvacuolated fibers. The inclusion body of inclusion-body myopathy muscle was originally described ultrastructurally as a cluster of tubulofilaments of unknown molecular composition. <ref type="bibr" target="#b13">14</ref> Subsequently, our cytochemical, immunocytochemical, and ultrastructural studies have demonstrated two major types of intracellular inclusions in the inclusion-body myopathies. <ref type="bibr" target="#b4">5</ref> Light-microscopically, there are rounded, plaque-like inclusions containing mainly amyloid-␤ and various-sized squiggly, linear inclusions mainly composed of phosphorylated tau protein. <ref type="bibr" target="#b4">5</ref> Both types of inclusions contain several accumulated proteins, some of which are present in both. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b14">15</ref> Both forms of inclusions are "amyloid" positive, as evidenced by their reactivity with crystal violet, thioflavin S, and Congo red stains, implying that they contain proteins in the ␤-pleated sheet configuration. <ref type="bibr" target="#b4">5</ref> Ultrastructurally, amyloid-␤-immunoreactive inclusions appear as aggregates of 6 to 10 nm amyloid-like fibrils and amorphous material, whereas inclusions containing phosphorylated tau protein appear as 15 to 21 nm paired helical filaments. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b14">15</ref> In general, more than 20 unrelated proteins, including, amyloid-␤, prion, tau, and transthyretin, abnormally unfold and self-aggregate to form ␤-pleated sheet amyloid. <ref type="bibr" target="#b35">36</ref> Although amyloid fibrils were previously considered to be cytotoxic, there is current experimental evidence that preamyloid complexes or aggregates, either diffuse or in a protofibril stage, can be very cytotoxic. <ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref> Mechanisms responsible for formations of the multiprotein inclusions in the inclusion-body myopathy muscle are not understood, but unfolding and misfolding of the proteins probably play a role. In general, protein aggregation is considered to be caused by binding of partly unfolded or misfolded polypeptides induced by interaction among their inappropriately exposed hydrophobic surfaces. <ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref> Those interactions were recently shown to be highly specific. <ref type="bibr" target="#b38">39</ref> Aggregates of improperly folded proteins are usually cytoplasmic and occasionally nuclear; correctly folded (normal) proteins are usually soluble, structural, or associated with cell membranes. <ref type="bibr" target="#b37">38</ref> Unfolding or misfolding of otherwise normal proteins can occur in vivo and in vitro under several circumstances, including macromolecular crowding, oxidative stress, exposure to toxins, and "aging." <ref type="bibr" target="#b37">38</ref> Markers of oxidative stress are increased in the inclusion-body myopathy muscle, <ref type="bibr" target="#b4">5</ref> and this mechanism could also contribute to abnormal folding or misfolding of proteins. Variously mutated proteins have a strong propensity to unfold or misfold. <ref type="bibr" target="#b37">38</ref> Aggregations of proteins into insoluble intracellular complexes and inclusion bodies have been proposed to be importantly related to several neurodegenerative disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Parkinson's disease. <ref type="bibr" target="#b37">38</ref> In accordance with this proposal are our recent studies demonstrating the unfolded protein response in the muscle of patients with sporadic inclusion-body myopathies. <ref type="bibr" target="#b39">40</ref> The unfolded protein response is indicative of the endoplasmic reticulum stress and the presence there of the improperly folded proteins. <ref type="bibr" target="#b40">41</ref> Several of the proteins accumulated in inclusion-body myopathy muscle fibersincluding, amyloid-␤, prion, phosphorylated tau, presenilin-1, ␣-synuclein, and superoxide dismytase 1 (SOD1)-have the propensity to pathologically unfold/misfold and thereby could contribute to the endoplasmic reticulum stress in the inclusion-body myopathies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key Role of Intracellular Accumulation of Amyloid-␤ Precursor Protein/Amyloid-␤ in Inclusion-Body Myopathy Muscle Fibers</head><p>We have proposed a key upstream or mid-stream role of increased intracellular amyloid-␤ precursor protein/amyloid-␤ in the pathogenesis of both sporadic and hereditary inclusion-body myopathies, suggesting that it is causing abnormal signal transduction, modulation of other genes, induction of oxidative stress, mitochondrial malfunction, and other abnormalities. <ref type="bibr" target="#b4">5</ref> Our hypothesis is supported by our tissueculture studies, which have shown the following:</p><p>1. Experimental overexpression of amyloid-␤ precursor protein through direct amyloid-␤ precursor protein gene transfer (via adenovirus vector) into human normal, rather mature, cultured muscle fibers induced several aspects of the inclusion-body myopathy pathologic phenotype, including vacuolation, intracellular congophilia, nuclear paired helical filaments, and abnormal mitochondria. 42,43 2. In cultured hereditary inclusion-body myopathy muscle fibers, an amyloid-␤ precursor protein overexpression, presumably genetically determined, preceded other detectable inclusion-body myopathy-like abnormalities. 5 3. In contrast to normal control cultured human muscle, both experimentally and genetically amyloid-␤ precursor protein-overexpressing cultured muscle fibers had abnormal neuromuscular junctions and could not become innervated by cocultured fetal-rat spinal cord neurons. <ref type="bibr" target="#b43">44</ref> Those results led us to propose that in inclusion-body myopathy, muscle intracellular amyloid-␤ precursor protein overexpression is responsible for the postulated "myogenous denervation" and for the recently reported neuromuscular junction abnormalities in inclusion-body myopathy biopsies. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b43">44</ref> Additional support for our hypothesis of an intracellular toxicity of amyloid-␤ precursor protein and amyloid-␤ in the inclusion-body myopathy pathogenesis was provided by two transgenic mouse models overexpressing amyloid-␤ precursor protein within muscle fibers. Some aspects of the human inclusion-body myopathy pathology were produced but only during aging of these mice. <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b7">8</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cholesterol and Related Mechanisms in the Inclusion-Body Pathogenesis</head><p>Cholesterol is a component of native apolipoprotein-E-containing lipoprotein particles. <ref type="bibr" target="#b44">45</ref> We recently showed that inclusion-body myopathy muscle fibers contained accumulations of free (nonesterified) cholesterol that colocalized with low-density lipoprotein receptor (LDLR) and very lowdensity lipoprotein receptor (VLDLR) immunoreactive inclusions, as well as with amyloid-␤ and phosphorylated tau protein. <ref type="bibr" target="#b45">46</ref> This suggested that in inclusion-body myopathy muscle fibers, accumulation of free cholesterol may represent another consequence, in addition to apolipoprotein-E accumulation, of the increased expression and ectopic accumulation of LDLR and VLDLR. <ref type="bibr" target="#b45">46</ref> Most recently, we demonstrated that caveolin-1, an intracellular transporter of cholesterol, is accumulated in inclusion-body myopathy muscle fibers, where it colocalizes with both free cholesterol and amyloid-␤. <ref type="bibr" target="#b46">47</ref> Caveolin-1, a major protein of plasmalemmal microdomain caveolae, binds cholesterol and influences its intracellular traffic and homeostasis. <ref type="bibr" target="#b47">48</ref> Our studies suggest that within inclusion-body myopathy muscle fibers, traffic of cholesterol is perturbed, resulting in its demonstrated accumulation there. Experimentally, cholesterol influences amyloid-␤ precursor protein processing, resulting in increased amyloid-␤ production, and it increases amyloid-␤ amyloidogenesis. <ref type="bibr" target="#b45">46</ref> Loading cultured cells with free cholesterol increased generation of amyloid-␤ from amyloid-␤ precursor protein, whereas cholesterol depletion did the opposite. <ref type="bibr" target="#b45">46</ref> The mechanism by which cholesterol influences amyloid-␤ precursor protein processing is not known, but one possibility could involve direct or indirect inhibition of the amyloid-␤ precursor protein ␣-secretase. <ref type="bibr" target="#b45">46</ref> Cholesterol binds amyloid-␤ and, by altering amyloid-␤ conformation, enhances its amyloidogenic ("seeding") properties. <ref type="bibr" target="#b29">30</ref> We propose that within inclusion-body myopathy muscle fibers, cholesterol, instead of being properly metabolized or cleared, is deposited, in spatial association with lipoprotein receptors, apolipoprotein-E and caveolin-1, at sites of amyloid-␤ accumulation and possibly at sites of amyloid-␤ precursor protein processing. At those sites, cholesterol could be increasing amyloid-␤ production and inducing amyloid-␤ amyloidogenesis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Possible Role of Muscle-Fiber Aging</head><p>Sporadic inclusion-body myositis typically becomes clinically manifest after age 50 years and more often in the sixties and seventies. Among sporadic "inflammatory myopathy" patients, the above-described specific degenerative accumulations of proteins, messenger ribonucleic acids, and cholesterol (see below) within muscle fibers occur only in sporadic inclusion-body myositis, not in polymyositis or dermatomyositis. But they do occur in the hereditary inclusion-body myopathies, which typically lack the lymphocytic inflammatory component. We suggest that those accumulations are related to an aging-based degenerative pathogenic cascade. In the hereditary inclusionbody myopathies, the causative gene abnormality exists from conception but does not produce clinically evident muscle damage until the second, third, or fourth decade of life. We postulate that a specific hereditary inclusion-body myopathy genetic defect, combined with the adult "earlyaging" muscle fiber milieu, leads to the hereditary inclusionbody myopathy characteristic of vacuolar degeneration. In the cellular milieu of the aging muscle fiber, there can be diminished homeostatic mechanisms caused by either underexpression of "youthful" genes encoding beneficial cellular factors or overexpression of yet unknown "aging" genes encoding toxic cellular factors.</p><p>For example, cellular aging has been shown to promote accumulation of abnormal proteins and slow the degradation rate of normal and abnormal proteins. <ref type="bibr" target="#b37">38</ref> The unfolding knowledge of aging-related protein misfolding and aggregation could clarify mechanisms presumably relevant to the inclusion-body myopathies and possibly help to develop treatment approaches.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 Hereditary Inclusion-Body Myopathies</head><label>1</label><figDesc></figDesc><table><row><cell>Gene/Linkage</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0">Journal of Child Neurology / Volume 18, Number 3, March 2003</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1">Carrell-Krusen Symposium / Askanas and Engel</note>
		</body>
		<back>

			<div type="funding">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Our studies described in this review were supported in part by the National Institutes of Health (grants NS34103 and AG16768), the Muscular Dystrophy Association and Alzheimer Foundation, and the Helen Lewis, Sheldon Katz, and Ron Stever Research Funds.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Inflammatory muscle diseases</title>
		<author>
			<persName><forename type="first">Hilton-Jones D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="591" to="596" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The molecular and cellular pathology of inflammatory muscle diseases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="300" to="306" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">New insights, current concepts in the pathophysiology of inflammatory myopathies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mendell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Immunotherapy</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="12" to="16" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Treatment of inclusion-body myositis and hereditary inclusion-body myopathy with reference to pathogenic mechanism. Personal experiences</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Inclusion-Body Myositis and Myopathies</title>
				<editor>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Serratrice</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</editor>
		<meeting><address><addrLine>Cambridge, United Kingdom</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<date type="published" when="1998">1998</date>
			<biblScope unit="page" from="351" to="382" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Inclusion-body myositis: Newest concepts of pathogenesis and relation to aging and Alzheimer disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-s myopathy similar to human inclusion body myositis</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Hearn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Ogburn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="1679" to="1686" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Amyloid-beta deposition in skeletal muscle of transgenic mice: Possible model of inclusion body myopathy</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fukuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="1687" to="1693" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Inclusion body myositis-like phenotype induced by transgenic overexpression of ␤APP in skeletal muscle</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Sugarman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Yamasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Oddo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="8334" to="8339" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Inflammation in dysferlin myopathy: Immunohistochemical characterization of 13 patients</title>
		<author>
			<persName><forename type="first">E</forename><surname>Gallardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rojas-Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>De Luna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="2136" to="2138" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Partial laminin ␣2 chain deficiency in a patient with myopathy resembling inclusion body myositis</title>
		<author>
			<persName><forename type="first">Di</forename><surname>Blasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pareyson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="811" to="816" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Fitzsimmons</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Facioscapulohumeral muscular dystrophy</title>
				<imprint>
			<date type="published" when="1999">1999</date>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="501" to="511" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">New advances in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="732" to="741" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Hereditary inclusion-body myopathies</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">The Molecular and Genetic Basis of Neurologic and Psychiatric Disease</title>
				<editor>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Rosenberg</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Prusiner</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">S</forename><surname>Dimauro</surname></persName>
		</editor>
		<meeting><address><addrLine>Philadelphia</addrLine></address></meeting>
		<imprint>
			<publisher>Butterworth-Heinemann</publisher>
		</imprint>
	</monogr>
	<note>3rd ed. in press</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Inclusion body myositis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Yunis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Samaha</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lab Invest</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="240" to="248" />
			<date type="published" when="1971">1971</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Newest approaches to diagnosis and pathogenesis of sporadic inclusion-body myositis and hereditary inclusion-body myopathies, including molecular-pathologic similarities to Alzheimer disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Inclusion-Body Myositis and Myopathies</title>
				<editor>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Serratrice</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</editor>
		<meeting><address><addrLine>Cambridge, United Kingdom</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<date type="published" when="1998">1998</date>
			<biblScope unit="page" from="3" to="78" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Late-juvenile sporadic inclusion body myositis: A newly recognized syndrome</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="439" to="440" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Vall22lle Allele</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="544" to="549" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The UDP-N-acetylglucosamine 2-epimerase/N acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy</title>
		<author>
			<persName><forename type="first">I</forename><surname>Eisenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Avidan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Potikha</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="83" to="87" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Distal myopathy with rimmed vacuoles: Novel mutations in the GNE gene</title>
		<author>
			<persName><forename type="first">H</forename><surname>Tomimitsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shimizu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="451" to="454" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">A novel mutation in the GNE gene and a linkage disequilibrium in Japanese pedigrees</title>
		<author>
			<persName><forename type="first">A</forename><surname>Arai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ikeuchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="516" to="519" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Detection of two mutant alleles in the UDP-N-acetylglucosamine 2-epimerase/Nacetylmannosamine kinase gene (GNE) in a cohort of patients with sporadic and hereditary inclusion body myopathies (IBM)</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">M</forename><surname>Vasconcelos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Raghavan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Granger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">A390</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver</title>
		<author>
			<persName><surname>Stäschet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hinderlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Weise</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">272</biblScope>
			<biblScope unit="page" from="24319" to="24324" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Primary structure and expression analysis of human UDP-N-acetyl-glucosamine-2-epimerase/Nacetylmannosamine kinase, the bifunctional enzyme in neuraminic acid biosynthesis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Lucka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Danker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">454</biblScope>
			<biblScope unit="page" from="341" to="344" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">UDP-GlcNAc 2-epimerase: A regulator of cell surface sialylation</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">T</forename><surname>Keppler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hinderlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Langner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">284</biblScope>
			<biblScope unit="page" from="1372" to="1376" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Enhanced detection of congored positive amyloid deposits in muscle fibers of inclusion-body myositis and brain of Alzheimer disease using fluorescence technique</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="1265" to="1267" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Use of antineurofilament antibody to identify paired-helical filaments in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="389" to="391" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Rapid examination of muscle tissuean improved trichrome method for fresh-frozen biopsy sections</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Cunningham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="919" to="923" />
			<date type="published" when="1963">1963</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Immunocytochemical localization of ubiquitin in inclusion-body myositis allows its light-microscopic distinction from polymyositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Serdaroglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="460" to="461" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Ubiquitin immunostaining and inclusion body myositis: Study of 30 patients with inclusion body myositis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Prayson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Cohen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="887" to="892" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">New autosomal-dominant inclusion-body myopathy (AD-IBM) with many congophilic muscle nuclei that contain paired-helical filaments (PHFs) composed of phosphorylated tau</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Simmons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page">A204</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bilak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="774" to="786" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="864" to="872" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Partial expression of oculopharyngeal muscular dystrophy (OPMD) muscle fibers of the intracellular phenotype of sporadic inclusion-body myositis (s-IBM)</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sarkozi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page">A331</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Hereditary inclusion body myopathies</title>
		<author>
			<persName><forename type="first">Fms</forename><surname>Tomé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fardeau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="453" to="459" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">The Alzheimer family of diseases: Many etiologies, one pathogenesis?</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hardy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="2095" to="2097" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Danger-misfolding proteins</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tjt</forename><surname>Pinheiro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">416</biblScope>
			<biblScope unit="page" from="483" to="484" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bucciantini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Giannoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chiti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">416</biblScope>
			<biblScope unit="page" from="507" to="511" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Sherman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuron</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="15" to="32" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Specificity in intracellular protein aggregation and inclusion body formation</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Rajan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Illing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Bence</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="13060" to="13065" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Evidence of endoplasmic reticulum stress and unfolded protein response in inclusion-body myositis (IBM) muscle</title>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page">A491</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">The unfolding tale of the unfolded protein response</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Hendershot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="827" to="830" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Transfer of ␤-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Baque</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="1314" to="1319" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">␤APP gene transfer into cultured human muscle induces inclusion-body myositis aspects</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="2155" to="2158" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Impaired innervation of cultured human muscle overexpressing ␤APP experimentally and genetically: Relevance to inclusion-body myopathies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="3201" to="3205" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Mahley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Rall</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Metabolic and Molecular Bases of Inheritied Diseases</title>
				<editor>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Scriver</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Beaudet</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Sly</surname></persName>
		</editor>
		<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>McGraw-Hill</publisher>
			<date type="published" when="2001">2001</date>
			<biblScope unit="page" from="2863" to="2913" />
		</imprint>
	</monogr>
	<note>8th ed</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle</title>
		<author>
			<persName><forename type="first">M</forename><surname>Jaworska-Wilczynska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Wilczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="438" to="445" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Abnormal accumulation of caveolin-1 and its co-localization with cholesterol, amyloid-␤ and phosphorylated tau in inclusion-body myositis (IBM) muscle</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kefi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page">A391</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Cholesterol and caveolae: Structural and functional relationships</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Fielding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Fielding</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Acta</title>
		<imprint>
			<biblScope unit="volume">1529</biblScope>
			<biblScope unit="page" from="210" to="222" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
